<DOC>
	<DOCNO>NCT00689936</DOCNO>
	<brief_summary>The purpose study compare safety efficacy Lenalidomide plus low dose dexamethasone combination melphalan , prednisone thalidomide .</brief_summary>
	<brief_title>Study Determine Efficacy Safety Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan , Prednisone , Thalidomide Patients With Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description>CC-5013-MM020/IFM 07-01 Phase III , multicenter , randomize , open-label , 3-arm study compare efficacy safety two Lenalidomide plus low-dose dexamethasone regimen give two different duration time ( i.e. , progressive disease [ PD ] maximum 18 four-week cycle ) MPT give maximum 12 six-week cycle .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Must understand voluntarily sign informed consent form 2 . Age ≥ 18 year time sign consent 3 . Previously untreated , symptomatic multiple myeloma define 3 criterion : MM diagnostic criterion ( 3 require ) : Monoclonal plasma cell bone marrow ≥10 % and/or presence biopsyproven plasmacytoma Monoclonal protein present serum and/or urine Myelomarelated organ dysfunction ( least one follow ) [ C ] Calcium elevation blood ( serum calcium &gt; 10.5 mg/dl upper limit normal ) [ R ] Renal insufficiency ( serum creatinine &gt; 2 mg/dl ) [ A ] Anemia ( hemoglobin &lt; 10 g/dl 2 g &lt; laboratory normal ) [ B ] Lytic bone lesion osteoporosis AND measurable disease protein electrophoresis analysis define follow : IgG multiple myeloma : Serum monoclonal paraprotein ( Mprotein ) level ≥ 1.0 g/dl urine Mprotein level ≥ 200 mg/24 hour IgA multiple myeloma : Serum Mprotein level ≥ 0.5 g/dl urine Mprotein level ≥ 200 mg/24 hour IgM multiple myeloma ( IgM Mprotein plus lytic bone disease document skeletal survey plain film ) : Serum Mprotein level ≥ 1.0 g/dl urine Mprotein level ≥ 200mg/24hours IgD multiple myeloma : Serum Mprotein level ≥ 0.05 g/dl urine Mprotein level ≥ 200 mg/24 hour Light chain multiple myeloma : Serum Mprotein level ≥ 1.0 g/dl urine Mprotein level ≥ 200 mg/24 hour AND least 65 year age old , young 65 year age , candidate stem cell transplantation : The patient decline undergo stem cell transplantation Stem cell transplantation available patient due cost reason 4 . ECOG performance status 0 , 1 , 2 5 . Able adhere study visit schedule protocol requirement 6 . Females childbearing potential ( FCBP ) ^2 : 1 . Must agree undergo two medically supervised pregnancy test prior start study therapy either Rd MPT . The first pregnancy test perform within 1014 day prior start Rd MPT second pregnancy test perform within 24 hour prior start Rd MPT . She must also agree ongoing pregnancy test course study end study therapy . This apply even patient practice complete continue sexual abstinence . 2 . Must commit either continued abstinence heterosexual intercourse ( must review monthly basis ) agree use able comply effective contraception without interruption , 28 day prior start study drug , study therapy ( include period dose interruption ) , 28 day discontinuation study therapy . 7 . Male Patients : 1 . Must agree use condom sexual contact FCBP , even vasectomy , throughout study drug therapy , dose interruption cessation study therapy . 2 . Must agree donate semen study drug therapy period end study drug therapy . 3 . Must practice complete abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 28 day follow study drug discontinuation , even undergone successful vasectomy . 8 . All patient must : 1 . Have understand study drug could potential teratogenic risk . 2 . Agree abstain donate blood take study drug therapy follow discontinuation study drug therapy . 3 . Agree share study medication another person . All FCBP male patient must counsel pregnancy precaution risk fetal exposure . 1 . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid [ i.e. , less equal equivalent dexamethasone 40 mg/day 4 day ; short course steroid treatment must give within 14 day randomization ] ) . 2 . Any serious medical condition place patient unacceptable risk participates study . Examples medical condition , limited , patient unstable cardiac disease define : Cardiac event MI within past 6 month , NYHA heart failure class IIIIV , uncontrolled atrial fibrillation hypertension ; patient condition require chronic steroid immunosuppressive treatment , rheumatoid arthritis , multiple sclerosis lupus , likely need additional steroid immunosuppressive treatment addition study treatment . 3 . Pregnant lactating female . 4 . Any following laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL ( 1.0 x 109/L ) Untransfused platelet count &lt; 50,000 cells/µL ( 50 x 10^9/L ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) 5 . Renal failure require hemodialysis peritoneal dialysis . 6 . Prior history malignancy , multiple myeloma , unless patient free disease ≥ 3 year . Exceptions include follow : Basal cell carcinoma skin Squamous cell carcinoma skin Carcinoma situ cervix Carcinoma situ breast Incidental histological finding prostate cancer ( TNM stage T1a T1b ) 7 . Patients unable unwilling undergo antithrombotic therapy . 8 . Peripheral neuropathy &gt; grade 2 severity . 9 . Known HIV positivity active infectious hepatitis , type A , B , C. Primary AL ( immunoglobulin light chain ) amyloidosis myeloma complicate amyloidosis . 1 A variety type end organ dysfunction occasionally occur lead need therapy . Such dysfunction sufficient support classification myeloma proven myelomarelated . 2 A FCBP sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal ( i.e. , amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>newly diagnose multiple myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>phase III</keyword>
</DOC>